Scarica l'app Stockscreener
32.75
0.79%
-0.26
Precedente Chiudi:
$33.01
Aprire:
$32.8
Volume 24 ore:
998.70K
Relative Volume:
1.05
Capitalizzazione di mercato:
$1.95B
Reddito:
-
Utile/perdita netta:
$-131.11M
Rapporto P/E:
-15.06
EPS:
-2.1745
Flusso di cassa netto:
$-102.47M
1 W Prestazione:
+6.96%
1M Prestazione:
+28.84%
6M Prestazione:
+11.74%
1 anno Prestazione:
+219.82%
Intervallo 1D:
$31.09
$33.27
Intervallo di 1 settimana:
$30.01
$33.27
Portata 52W:
$9.96
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
32.75 | 1.95B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Guggenheim | Buy |
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark - marketscreener.com
(TYRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2500 Value Benchmark - marketscreener.com
10 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Tyra Biosciences, Inc.(NasdaqGS:TYRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com - Investing.com Nigeria
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks - Moomoo
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026 - Stock Titan
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA) - TradingView
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - Sahm
TYRA Forecast — Price Target — Prediction for 2027 - TradingView
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
JonesTrading Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $56 - 富途牛牛
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences (TYRA) Slips 2.58%: Support Level in Focus After Weekly DeclineReversal Trade - dars.gov.et
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA) - The Globe and Mail
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tyra Biosciences Inc (TYRA) Institutional Confidence - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TYRA PE Ratio & Valuation, Is TYRA Overvalued - Intellectia AI
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):